Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Non-Current Assets (2016 - 2025)

Moleculin Biotech's Non-Current Assets history spans 10 years, with the latest figure at $12.4 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $12.4 million for Q4 2025, up 6.04% from a year ago — trailing twelve months through Dec 2025 was $49.1 million (up 3.91% YoY), and the annual figure for FY2025 was $12.4 million, up 6.04%.
  • Non-Current Assets for Q4 2025 was $12.4 million at Moleculin Biotech, roughly flat from $12.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $12.5 million in Q2 2025 to a low of $11.5 million in Q1 2022.
  • The 5-year median for Non-Current Assets is $11.8 million (2022), against an average of $11.9 million.
  • The sharpest move saw Non-Current Assets decreased 2.2% in 2021, then increased 6.04% in 2025.
  • Year by year, Non-Current Assets stood at $11.6 million in 2021, then increased by 2.01% to $11.8 million in 2022, then rose by 1.0% to $11.9 million in 2023, then dropped by 1.78% to $11.7 million in 2024, then increased by 6.04% to $12.4 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $12.4 million, $12.5 million, and $12.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.